Galderma Group company profile
Company profile
Galderma Group has 7,676 employees and is headquartered in Zug, Switzerland.
Restylane, Dysport, Azzalure and Sculptra are among the injectable aesthetics brands people know best, while Cetaphil and ALASTIN cover dermatological skincare and Soolantra, Epiduo and Differin serve therapeutic dermatology. Galderma Group AG works across the dermatology market worldwide, offering aesthetic injectables, skincare products and treatments for skin conditions. Its portfolio also includes Oracea, AKLIEF, NEMLUVIO and Relfydess, and the company provides services alongside its brands. Its therapeutic range also includes Loceryl, Benzac and Metvix.
In the fiscal year ended December 2025, the company reported revenue of USD 5.2 billion, up 18% from the prior year, and net income of USD 613 million. Galderma was founded in 1981, is headquartered in Zug, Switzerland, and employed 7,676 people. The figures are reported in US dollars.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Switzerland
- Headquarters
- Zählerweg 10, 6300, Zug
- Employees
- 7,676
- Chief executive
- Flemming Ornskov
- Founded
- 1981
- Fiscal year
- January - December
- Listing
- GALD · SIX
- Indices
- SMI
- Currency
- CHF
- ISIN
- CH1335392721
- Website
- galderma.com
Galderma Group and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Galderma GroupGALD | Switzerland | $51.94B | 7,676 | 19.1% | 64.5 |
| Sandoz GroupSDZ | Switzerland | $43.57B | 20,000 | 9.3% | 72.3 |
| HaleonHLN | United Kingdom | $40.15B | 24,535 | 23.5% | 19.3 |
| MerckMRK | Germany | $71.52B | 61,949 | 17.0% | 33.9 |
| Swedish Orphan BiovitrumSOBI | Sweden | $16.27B | 2,207 | 30.9% | 25.0 |
| IpsenIPN | France | $14.2B | 5,535 | 27.4% | 25.5 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
